Poster Presentations:
Nonclinical Toxicology Profile of AMG 517, A Novel TRPV1 Antagonist Considered for Clinical Use as a Pain Therapeautic. N.B. Ernst, D.N. Hovland, S. Surapaneni, A. Back, J. Wisler and M.Cosenza. Toxicology, Amgen, Thousand Oaks, CA.
The Toxicity Assessment of Two Anti-Angiogenic Small Molecules in Sprague-Dawley Rats and Beagle Dogs. MD Todd, I Hayward, R Willis, C Zimmermann, J Engelhardt, M Cosenza, T Polverino and S Wolford. Department of Toxicology, Cancer Biology and Pathology, Amgen, Inc., Thousand Oaks, CA. Covance Inc., Madison, WI. Presented #1675 at SOT Annual Meeting March 2006.
Influence of Impurities on Genotoxicity Findings of a Drug Candidate – A Case Study. SG Sawant, RT Dunn, T Day, CA Afshari, M Cosenza, M Todd, H Murli, GL Erexson, , VO Wagner. Department of Toxicology, Amgen Inc., Thousand Oaks, CA, Covance Inc., Vienna, VA. and BioReliance Corp., Rockville, MD. Presented #555 at SOT Annual Meeting March 2006.
Assessment of the Impact of Cardiotoxicity Diagnoosis by Troponin and Genomics Measures. R Dunn, P Nordone, S Thukral, L Healy, E Galambos, P Sabitsana, A Fosdick, J Urgino, R Hu, M Cosenza, C Afshari. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA. Presented #1534 at SOT Annual Meeting March 2006.
Safety Evaluation of Intra-articularly Injected AMG 108 and Kineret in New Zealand White Rabbit. A Ndifor, A Nguyen, T Sun, M Cosenza, A LaRochelle and J Pletcher. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA and Charles River Laboratories, Worcester, MA. Presented #1683 at SOT Annual Meeting March 2006.
Characterization of a Cynomolgus Monkey Kidney-Derived Cell Line, JTC-12, for Suitability in Toxicity Evaluations. DD Baker, S Sawant, M Cosenza, C Afshari and R Dunn. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA. Presented #1967 at SOT Annual Meeting in March 2006.
Increased Bone Mass is Highly Correlated With Increased Bone Strength in Cynomolgus Monkeys Treated with AMG 162, a Fully Human RANKL Antibody. JE Atkinson, P Cranmer, T Saunders, M Niehaus, SY Smith, A Varela, MS Ominsky, ME Cosenza, PJ Kostenuik. Department of Toxicology, Amgen Inc., Thousand Oaks, CA. Presented at Bone quality: What is it and Can we Measure It? May 2-3, 2005. Bethesda, MD.
Utilization of Multiple Endpoints to Investigate Differential Toxicity Produced by Topoisomerase II Inhibitors, Doxorubicin and Etoposide. R T Dunn, E S Galambos,
L Healy, R Morgan, J Yamada, H Hamadeh, A Kwok, M E Cosenza, C Afshari. Department of Toxicology, Amgen Inc., Thousand Oaks, CA. Presented #1784 at SOT Annual Meeting March 2005.
Safety Assessment of a Novel P38 Inhibitor in Cynomolgus Monkeys Following Daily Oral Dosings. S L Wild; T Pabst Marra; G. Jang; W Min; R House; A Mould; M Cosenza. Department of Toxicology, Amgen Inc., Thousand Oaks, CA; Covance Laboratories Inc., Madison, WI; DynPort Vaccine Co. LLC, Frederick, MD. Presented #467 at Annual SOT Meeting March 2005.
A 4-Week Subcutaneous Injection Toxicity Study of PTH-FC with a 4-Week Recovery Period in the Albino Rat. J E Atkinson, C Alcalde, M E Cosenza, S Y Smith, N Doyle,
C R Dunstan, C Zimmermann and P Kosstenuik. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented #686 at SOT Annual Meeting March 2004.
Gene Expression Analysis of Proximal Tubular and Glomerular Nephroxicants.
PJ Nordone, R Hu, L Sullivan, C Piddington, VD Fitzpatrick, L Healy, D Wen, H Hamadeh, ME Cosenza, CA Afshari, SK Thukral. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented #47 at Environmental Mutagen Society Meeting May 2003.
Application of Gene Expression Analysis to Classify and Predict Nephrotoxicant Pathology. SK Thukral, PJ Nordone, R Hu, L Sullivan, VD Fitzpatrick, L Healy, M Bass, D Wen, H Hamadeh, ME Cosenza, CA Afshari. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented #14 at ACT Meeting November 2003.
Hemolytic Potential of Vehicles used for Rapid in vivo Screening of Small Molecules.
S Sawant, S Greene, M E. Cosenza, S Neervannan, A Gore, A Schultz, J Jona, S Goel and H Davis. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented at SOT Annual Meeting March 2002.
Metabonomics: A Sensitive Technique to Assess Toxicity. H Virissimo, DM Smith, B Bolon, ME Cosenza, H Davis, S Greene, SG Sawant. Amgen, Thousand Oaks, CA. Presented # P-7 at ACT Meeting November 2002.
Comparative Pathology of Vehicles Used for Rapid In Vivo Screening of Small Molecules. SL Wild, ME Cosenza, L Sullivan, C DiPalma, T Pabst, A Mancini, S Shoup, I Nazario, S Neervannan, IJ Hayward, B Bolon, and H Davis. Amgen, Inc., Thousand Oaks, CA, Poster #1782, Presented at SOT Meeting March 2001.
Cytoplasmic Vacuoles in Renal Tubular Epithelium of Mice Given Polyethylene Glycol (PEG) Conjugated Protein are Reduced by Altering PEG Size and Conformation. B Bolon, J Faust, N Storm, D Litzinger, Me Cosenza, O Kinstler and C Gregg. Amgen, Thousand Oaks, CA, Poster #1788, Presented at SOT Meeting March 2001.
A Phase I/II Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Potential Efficacy of Human tumor Necrosis Factor Binding Protein Pegylated dimer (TNFbp) in Patients with Active Rheumatoid Arthritis. C.K. Edwards, G. Henry, J. Seely, S.M. Martin, C. Yee, A.M. Bendele, T. Kohno, M.E. Cosenza, S. Lyons, D. McCabe. Keystone Symposia - Pathogenesis of RA and Mechanisms, Keystone, Colorado, January 23, 1998 - January 29, 1998.
Preclinical Toxicity Assessment of R-568 in Calcium Supplemented Dogs. ME Cosenza, O Lopez, D Dalgard, L Roskos, and H Davis. Abstract # 239, Presented at SOT Meeting March 1998.
In Vitro/In Vivo Correlation of Paraquat Induced Developmental Neurotoxicity,
M E Cosenza, J Bidanset, and D E Johnson, Poster #1251, Presented at SOT Meeting March 1996.
Preclinical Safety Testing of Drugs Produced by Biotechnology. Presented at the Corning Hazleton BioPharm Workshop, June 1996.
Two Week Inhalation Study In Rats With Methotrexate, C E Ulrich and M E Cosenza, Poster #539, Presented at SOT Meeting February 1992.
Two Week Dog Inhalation Study With Methotrexate, M E Cosenza and C E Ulrich, Poster # 540, Presented at SOT Meeting February 1992.
A Phase I/II Study To Evaluate The Safety, Immunogenicity, Pharmacokinetics And Potential Efficacy Of Human Tumor Necrosis Factor Binding Protein Pegylated Dimer (TNFbp) In Patients With Active Rheumatoid Arthritis. C.K. Edwards, , ME Cosenza, et. al., Keystone Symposium-Pathogenesis of RA and Mechanisms, Keystone, Colorado. SOT Meeting, Feb 1992.
The Toxicity Assessment of Two Anti-Angiogenic Small Molecules in Sprague-Dawley Rats and Beagle Dogs. MD Todd, I Hayward, R Willis, C Zimmermann, J Engelhardt, M Cosenza, T Polverino and S Wolford. Department of Toxicology, Cancer Biology and Pathology, Amgen, Inc., Thousand Oaks, CA. Covance Inc., Madison, WI. Presented #1675 at SOT Annual Meeting March 2006.
Influence of Impurities on Genotoxicity Findings of a Drug Candidate – A Case Study. SG Sawant, RT Dunn, T Day, CA Afshari, M Cosenza, M Todd, H Murli, GL Erexson, , VO Wagner. Department of Toxicology, Amgen Inc., Thousand Oaks, CA, Covance Inc., Vienna, VA. and BioReliance Corp., Rockville, MD. Presented #555 at SOT Annual Meeting March 2006.
Assessment of the Impact of Cardiotoxicity Diagnoosis by Troponin and Genomics Measures. R Dunn, P Nordone, S Thukral, L Healy, E Galambos, P Sabitsana, A Fosdick, J Urgino, R Hu, M Cosenza, C Afshari. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA. Presented #1534 at SOT Annual Meeting March 2006.
Safety Evaluation of Intra-articularly Injected AMG 108 and Kineret in New Zealand White Rabbit. A Ndifor, A Nguyen, T Sun, M Cosenza, A LaRochelle and J Pletcher. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA and Charles River Laboratories, Worcester, MA. Presented #1683 at SOT Annual Meeting March 2006.
Characterization of a Cynomolgus Monkey Kidney-Derived Cell Line, JTC-12, for Suitability in Toxicity Evaluations. DD Baker, S Sawant, M Cosenza, C Afshari and R Dunn. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA. Presented #1967 at SOT Annual Meeting in March 2006.
Increased Bone Mass is Highly Correlated With Increased Bone Strength in Cynomolgus Monkeys Treated with AMG 162, a Fully Human RANKL Antibody. JE Atkinson, P Cranmer, T Saunders, M Niehaus, SY Smith, A Varela, MS Ominsky, ME Cosenza, PJ Kostenuik. Department of Toxicology, Amgen Inc., Thousand Oaks, CA. Presented at Bone quality: What is it and Can we Measure It? May 2-3, 2005. Bethesda, MD.
Utilization of Multiple Endpoints to Investigate Differential Toxicity Produced by Topoisomerase II Inhibitors, Doxorubicin and Etoposide. R T Dunn, E S Galambos,
L Healy, R Morgan, J Yamada, H Hamadeh, A Kwok, M E Cosenza, C Afshari. Department of Toxicology, Amgen Inc., Thousand Oaks, CA. Presented #1784 at SOT Annual Meeting March 2005.
Safety Assessment of a Novel P38 Inhibitor in Cynomolgus Monkeys Following Daily Oral Dosings. S L Wild; T Pabst Marra; G. Jang; W Min; R House; A Mould; M Cosenza. Department of Toxicology, Amgen Inc., Thousand Oaks, CA; Covance Laboratories Inc., Madison, WI; DynPort Vaccine Co. LLC, Frederick, MD. Presented #467 at Annual SOT Meeting March 2005.
A 4-Week Subcutaneous Injection Toxicity Study of PTH-FC with a 4-Week Recovery Period in the Albino Rat. J E Atkinson, C Alcalde, M E Cosenza, S Y Smith, N Doyle,
C R Dunstan, C Zimmermann and P Kosstenuik. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented #686 at SOT Annual Meeting March 2004.
Gene Expression Analysis of Proximal Tubular and Glomerular Nephroxicants.
PJ Nordone, R Hu, L Sullivan, C Piddington, VD Fitzpatrick, L Healy, D Wen, H Hamadeh, ME Cosenza, CA Afshari, SK Thukral. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented #47 at Environmental Mutagen Society Meeting May 2003.
Application of Gene Expression Analysis to Classify and Predict Nephrotoxicant Pathology. SK Thukral, PJ Nordone, R Hu, L Sullivan, VD Fitzpatrick, L Healy, M Bass, D Wen, H Hamadeh, ME Cosenza, CA Afshari. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented #14 at ACT Meeting November 2003.
Hemolytic Potential of Vehicles used for Rapid in vivo Screening of Small Molecules.
S Sawant, S Greene, M E. Cosenza, S Neervannan, A Gore, A Schultz, J Jona, S Goel and H Davis. Department of Toxicology, Amgen, Inc., Thousand Oaks, CA. Presented at SOT Annual Meeting March 2002.
Metabonomics: A Sensitive Technique to Assess Toxicity. H Virissimo, DM Smith, B Bolon, ME Cosenza, H Davis, S Greene, SG Sawant. Amgen, Thousand Oaks, CA. Presented # P-7 at ACT Meeting November 2002.
Comparative Pathology of Vehicles Used for Rapid In Vivo Screening of Small Molecules. SL Wild, ME Cosenza, L Sullivan, C DiPalma, T Pabst, A Mancini, S Shoup, I Nazario, S Neervannan, IJ Hayward, B Bolon, and H Davis. Amgen, Inc., Thousand Oaks, CA, Poster #1782, Presented at SOT Meeting March 2001.
Cytoplasmic Vacuoles in Renal Tubular Epithelium of Mice Given Polyethylene Glycol (PEG) Conjugated Protein are Reduced by Altering PEG Size and Conformation. B Bolon, J Faust, N Storm, D Litzinger, Me Cosenza, O Kinstler and C Gregg. Amgen, Thousand Oaks, CA, Poster #1788, Presented at SOT Meeting March 2001.
A Phase I/II Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Potential Efficacy of Human tumor Necrosis Factor Binding Protein Pegylated dimer (TNFbp) in Patients with Active Rheumatoid Arthritis. C.K. Edwards, G. Henry, J. Seely, S.M. Martin, C. Yee, A.M. Bendele, T. Kohno, M.E. Cosenza, S. Lyons, D. McCabe. Keystone Symposia - Pathogenesis of RA and Mechanisms, Keystone, Colorado, January 23, 1998 - January 29, 1998.
Preclinical Toxicity Assessment of R-568 in Calcium Supplemented Dogs. ME Cosenza, O Lopez, D Dalgard, L Roskos, and H Davis. Abstract # 239, Presented at SOT Meeting March 1998.
In Vitro/In Vivo Correlation of Paraquat Induced Developmental Neurotoxicity,
M E Cosenza, J Bidanset, and D E Johnson, Poster #1251, Presented at SOT Meeting March 1996.
Preclinical Safety Testing of Drugs Produced by Biotechnology. Presented at the Corning Hazleton BioPharm Workshop, June 1996.
Two Week Inhalation Study In Rats With Methotrexate, C E Ulrich and M E Cosenza, Poster #539, Presented at SOT Meeting February 1992.
Two Week Dog Inhalation Study With Methotrexate, M E Cosenza and C E Ulrich, Poster # 540, Presented at SOT Meeting February 1992.
A Phase I/II Study To Evaluate The Safety, Immunogenicity, Pharmacokinetics And Potential Efficacy Of Human Tumor Necrosis Factor Binding Protein Pegylated Dimer (TNFbp) In Patients With Active Rheumatoid Arthritis. C.K. Edwards, , ME Cosenza, et. al., Keystone Symposium-Pathogenesis of RA and Mechanisms, Keystone, Colorado. SOT Meeting, Feb 1992.